Clinical trials of the Sputnik V vaccine among cancer patients may start in the coming months, TASS reports, references to Daria Egorova, senior researcher at the Laboratory of Genetic Engineering of Pathogenic Microorganisms at the Gamalei Center.
“We are currently planning that such researches will be launched in the next few months, and first of all they will be carried out on a group of patients who are currently in cancer remission, because we are going progressively to increase the degree of risk for the patients who will take part in the research”, she said at a press conference in Moscow.
Egorova clarified that in the instruction of Sputnik V use there is no clause prohibiting vaccinations for cancer patients, but there is an indication that the use of the drug involves risks.
Earlier, Iranian Foreign Minister Mohammad Javad Zarif said that the Russian Sputnik V vaccine was registered in Iran.
The Sputnik V vaccine was registered in August 2020. It is based on a well-studied platform of human adenovirus vectors and has already received regulatory approval in Russia, Belarus, Argentina, the UAE, Hungary, Serbia, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan. In India, the Russian drug is undergoing the third stage of testing, according to Venkatesh Varma, ambassador to Moscow, they plan to register the vaccine within several weeks.
